{"id":174,"date":"2024-08-23T21:27:12","date_gmt":"2024-08-23T13:27:12","guid":{"rendered":"https:\/\/flcube.com\/?p=174"},"modified":"2024-10-13T18:35:42","modified_gmt":"2024-10-13T10:35:42","slug":"ocumension-therapeutics-to-repurchase-shares-demonstrating-confidence-and-commitment-to-investor-rights","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=174","title":{"rendered":"Ocumension Therapeutics to Repurchase Shares, Demonstrating Confidence and Commitment to Investor Rights"},"content":{"rendered":"\n

Ocumension Therapeutics, a biopharmaceutical company based in China and listed on the Hong Kong Stock Exchange (HKG: 1477<\/a>), has declared its intent to proceed with a share repurchase program, targeting 10% of the total issued shares, excluding treasury shares. This initiative, which is not to exceed HKD 200 million, is underpinned by the company’s confidence in its value and a commitment to protecting investors’ rights.<\/p>\n\n\n\n

The company’s rationale for the repurchase is rooted in the robust health of its assets, the seamless expansion of its business operations, and the advancement of product research and development, all complemented by robust cash flow. Ocumension’s commercialization efforts for its core products have yielded substantial outcomes, with a 61.6% year-on-year increase in sales revenue to RMB 168 million in the first half of 2024 and a continued reduction in adjusted losses.<\/p>\n\n\n\n

In the pipeline, OT-1001, a groundbreaking drug for allergic conjunctivitis, is nearing marketing approval in China. OT-702, an aflibercept biosimilar, is in the regulatory approval phase, while OT-502, a dexamethasone implant, is being prepared for clinical filing. Bolstering its position further, Ocumension has entered into a strategic partnership with Alcon Laboratories Inc., a US-based firm, securing the research, development, manufacturing, and commercialization rights for several of Alcon’s market-ready products and one clinical-stage candidate within the Chinese market. Alcon is set to become a significant shareholder of Ocumension.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Ocumension Therapeutics, a biopharmaceutical company based in China and listed on the Hong Kong Stock…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[936,156,44],"class_list":["post-174","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-hkg-1477","tag-ocumension-therapeutics","tag-ophthalmology"],"yoast_head":"\nOcumension Therapeutics to Repurchase Shares, Demonstrating Confidence and Commitment to Investor Rights - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Ocumension Therapeutics, a biopharmaceutical company based in China and listed on the Hong Kong Stock Exchange (HKG: 1477), has declared its intent to proceed with a share repurchase program, targeting 10% of the total issued shares, excluding treasury shares. This initiative, which is not to exceed HKD 200 million, is underpinned by the company's confidence in its value and a commitment to protecting investors' rights.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=174\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ocumension Therapeutics to Repurchase Shares, Demonstrating Confidence and Commitment to Investor Rights\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=174\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-23T13:27:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-13T10:35:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=174#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=174\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Ocumension Therapeutics to Repurchase Shares, Demonstrating Confidence and Commitment to Investor Rights\",\"datePublished\":\"2024-08-23T13:27:12+00:00\",\"dateModified\":\"2024-10-13T10:35:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=174\"},\"wordCount\":237,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 1477\",\"Ocumension Therapeutics\",\"Ophthalmology\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=174#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=174\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=174\",\"name\":\"Ocumension Therapeutics to Repurchase Shares, Demonstrating Confidence and Commitment to Investor Rights - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-08-23T13:27:12+00:00\",\"dateModified\":\"2024-10-13T10:35:42+00:00\",\"description\":\"Ocumension Therapeutics, a biopharmaceutical company based in China and listed on the Hong Kong Stock Exchange (HKG: 1477), has declared its intent to proceed with a share repurchase program, targeting 10% of the total issued shares, excluding treasury shares. This initiative, which is not to exceed HKD 200 million, is underpinned by the company's confidence in its value and a commitment to protecting investors' rights.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=174#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=174\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=174#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ocumension Therapeutics to Repurchase Shares, Demonstrating Confidence and Commitment to Investor Rights\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ocumension Therapeutics to Repurchase Shares, Demonstrating Confidence and Commitment to Investor Rights - Insight, China's Pharmaceutical Industry","description":"Ocumension Therapeutics, a biopharmaceutical company based in China and listed on the Hong Kong Stock Exchange (HKG: 1477), has declared its intent to proceed with a share repurchase program, targeting 10% of the total issued shares, excluding treasury shares. This initiative, which is not to exceed HKD 200 million, is underpinned by the company's confidence in its value and a commitment to protecting investors' rights.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=174","og_locale":"en_US","og_type":"article","og_title":"Ocumension Therapeutics to Repurchase Shares, Demonstrating Confidence and Commitment to Investor Rights","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=174","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-08-23T13:27:12+00:00","article_modified_time":"2024-10-13T10:35:42+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=174#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=174"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Ocumension Therapeutics to Repurchase Shares, Demonstrating Confidence and Commitment to Investor Rights","datePublished":"2024-08-23T13:27:12+00:00","dateModified":"2024-10-13T10:35:42+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=174"},"wordCount":237,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 1477","Ocumension Therapeutics","Ophthalmology"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=174#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=174","url":"https:\/\/flcube.com\/?p=174","name":"Ocumension Therapeutics to Repurchase Shares, Demonstrating Confidence and Commitment to Investor Rights - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-08-23T13:27:12+00:00","dateModified":"2024-10-13T10:35:42+00:00","description":"Ocumension Therapeutics, a biopharmaceutical company based in China and listed on the Hong Kong Stock Exchange (HKG: 1477), has declared its intent to proceed with a share repurchase program, targeting 10% of the total issued shares, excluding treasury shares. This initiative, which is not to exceed HKD 200 million, is underpinned by the company's confidence in its value and a commitment to protecting investors' rights.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=174#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=174"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=174#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Ocumension Therapeutics to Repurchase Shares, Demonstrating Confidence and Commitment to Investor Rights"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/174","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=174"}],"version-history":[{"count":4,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/174\/revisions"}],"predecessor-version":[{"id":5915,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/174\/revisions\/5915"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=174"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=174"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=174"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}